Jingyuan Wang

Jingyuan Wang is the Investor Representative of Hongmei Technology, Deputy General Manager of Zhongshan Xiangshang Investment Management and Deputy General Manager of Zhongshan Xiangshang Private Equity Investment Fund Co., Ltd..With a professional background spanning law, investment and corporate governance, his work focuses on healthcare investment, private equity, asset restructuring and strategic capital operations. His experience covers corporate listings, cross-border M&A, equity investment and governance restructuring. By combining legal expertise with an investment and industrial perspective, Jingyuan works closely with companies on capital strategy, transaction execution and long-term business development. Through Hongmei Technology, his work has further extended into biotechnology and sustainable manufacturing. The company is advancing a large-scale non-grain carbon-source synthetic biology manufacturing project, combining non-food feedstocks, next-generation strains and AI-enabled enzyme systems to improve resource efficiency and industrial-scale biomanufacturing capabilities. The project also brings together themes such as green manufacturing, supply-chain resilience and more efficient use of biological resources, creating a natural connection between industrial development and ESG-oriented investment.

王靖远先生现任红莓科技公司代表投资人、中山香商投资管理有限公司副总经理以及中山香商私募股权投资基金有限公司副总经理。他拥有法律、投资及企业治理等多维度专业背景，长期参与大健康产业投资、私募股权投资、资产重整及战略资本运作。 他的实务经验覆盖企业上市、跨境并购、股权投资及治理重组等多个领域，并善于将法律判断、资本运作与产业视角结合，为企业提供从交易执行、资本规划到长期发展的综合支持。 通过红莓科技，其产业实践进一步延伸至合成生物与绿色制造领域。公司目前正推进万吨级非粮碳源合成生物制造项目，通过非粮原料、第三代菌种及 AI 酶系等技术路径，提升生物制造的资源利用效率与规模化生产能力。项目同时涉及绿色制造、供应链韧性及生物资源高效利用等方向，使其产业投资实践与 ESG 所关注的可持续产业发展形成较自然的结合。 在投资与企业管理实践中，王靖远先生长期关注公司治理、资本配置效率与长期价值创造，并持续推动资本、科技与可持续产业发展之间的连接。